- Douglas R Galasko, University of California, San Diego
- Todd E Golde, University of Florida
- Philip Scheltens, VU University Medical Center
Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom
Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.
Villemagne & colleagues discuss the Alzheimer’s Disease Neuroimaging Initiative, which represents a great opportunity to establish standards for the early diagnosis of Alzheimer’s disease, in a global effort to increase understanding of the pathophysiology of Alzheimer’s.
Wesnes reviews the attributes of automated and non-automated cognitive assessments and suggests that the choice of assessment type should depend on the criteria relevant to the clinical trial in question.
The US Lewy Body Dementia Association and the UK Lewy Body Society discuss how charities can significantly reduce the burden that Lewy body dementia has on families and society, and are an additional resource to clinical care.
Examination of subcortical hyperintensities revealed signs of small vessel disease, which may be differentially associated with specific cognitive functions and have potential clinical relevance as targets for treatment in Alzheimer’s disease (AD).
Monoclonal antibody DC8E8 disables a novel target on tau protein essential for its pathological function both in vitro and in vivo, and is a suitable candidate molecule for Alzheimer's disease immunotherapy.
Active vaccine AADvac1 validates the novel tau target revealed by monoclonal antibody DC8E8 by reducing Alzheimer's disease-type tau hyperphosphorylation by 95% in transgenic rats, and has now entered phase I clinical trials.
Jeromin and colleagues discuss the use of magnetic resonance imaging (MRI) as a neuroimaging approach in the development of novel treatments for Alzheimer's disease (AD), including its role as a biomarker in clinical trials.
Acetylcholinesterase inhibitor galantamine lowered the rate of whole brain atrophy, but not hippocampal atrophy, in mild cognitive impairment patients that carried the ε4 allele of apolipoprotein E only.
The following review has recently become free to access:
Kristin R Wildsmith, Monica Holley, Julie C Savage, Rebecca Skerrett, Gary E LandrethAlzheimer's Research & Therapy 2013, 5:33 (12 July 2013)
From the blog
Aims & scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.
The evolving field of traumatic brain injury
What do we currently know about chronic traumatic encephalopathy (CTE) and what are the most important questions in the field? Listen to a free podcast discussing this and more, as part of our special series on Traumatic Brain Injury.
Searching for biomarkers
As part of our special series on Peripheral Biomarkers, listen to a free podcast by Douglas Galasko about the advances and current issues in the search to identify blood biomarkers for Alzheimer's disease.